or protests should be filed on or before the comment date. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. Copies of this filing are on file with the Commission and are available for public inspection.

Linwood A. Watson, Jr.,

Acting Secretary.

[FR Doc. 97–7757 Filed 3–26–97; 8:45 am]

BILLING CODE 6717–01–P

ENVIRONMENTAL PROTECTION AGENCY

[FRL–5803–8]

National Drinking Water Advisory Council Consumer Confidence Working Group; Notice of Open Meeting

Under Section 10(a)(2) of Public Law 92–423, ''The Federal Advisory Committee Act,'' notice is hereby given for upcoming meetings of the Consumer Confidence Working Group of the National Drinking Water Advisory Council (established under the Safe Drinking Water Act, as amended (42 U.S.C. 300f *et seq.*)), to be held April 3, 1997, from 1:00 p.m. to 5:00 p.m. and April 4, 1997, from 9:00 a.m. to 5:00 p.m. at the Westin City Center, 1400 M Street NW, Washington, DC; and May 8, 1997, from 9:00 a.m. to 5:00 p.m. and May 9, 1997, from 9:00 a.m. to 3:00 p.m. at the Dupont Plaza Hotel, 1500 New Hampshire Ave. NW, Washington DC.

The purpose of the meetings is to discuss drafts of rule language and attendant documents. The meetings are open to the public, but seating is limited. Statements from the public will be taken at the end of the meeting if time allows.

For more information, please contact, Francoise M. Brasier, Designated Federal Officer, Consumer Confidence Working Group, U.S. EPA, Office of Ground Water and Drinking Water 5606, 401 M Street SW, Washington, D.C. 20460. The telephone number is Area Code 202–260–5668. The e-mail address is brasier.francoise & epamail.epa.gov.

Dated: March 12, 1997.

Charlene Shaw,

Designated Federal Officer, National Drinking Water Advisory Council.

[FR Doc. 97–7816 Filed 3–26–97; 8:45 am]

BILLING CODE 6560–50–M

FEDERAL MARITIME COMMISSION

Ocean Freight Forwarder License Applicants

Notice is hereby given that the following applicants have filed with the Federal Maritime Commission applications for licenses as ocean freight fowarders pursuant to section 19 of the Shipping Act of 1984 (46 U.S.C. app. 1718 and 46 CFR 510).

Persons knowing of any reason why any of the following applicants should not receive a license are requested to contact the Office of Freight Forwarders, Federal Maritime Commission, Washington, D.C. 10573.

Anchor Shipping and Chartering Co., 5619 Hazen Street, Houston, TX 77081, Ronny Gene Mollard, Sole Proprietor

Nick Rendon III International Inc., 139 Mitchell Avenue, Ste. 216, So. San Francisco, CA 94080, Officer: Nicholas Rendon III, President

Cargo America Group, Ltd., 4702 Lucerne Valley Road, Lilburn, Georgia 30247, Officers: Troy Abercrombie, President, Wanda Abercrombie, President

Dated: March 24, 1997.

Joseph C. Polking,

Secretary.

[FR Doc. 97–7779 Filed 3–26–97; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 21, 1997.

A. Federal Reserve Bank of New York (Christopher J. McCurdy, Senior Vice President) 33 Liberty Street, New York, New York 10045-0001:

1. BanPonce Corporation, Hato Rey, Puerto Rico; Poplar International Bank, Inc., Hato Rey, Puerto Rico; and BanPonce Financial Corp., Wilmington, Delaware; to acquire 100 percent of the voting shares of CBC Bancorp, Ltd., Chicago, Illinois, and thereby indirectly acquire Capitol Bank of Westmont, Westmont, Illinois, and Capitol Bank and Trust, Chicago, Illinois.

B. Federal Reserve Bank of Atlanta (Lois Berthaume, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303-2713:

1. Florida Bancshares, Inc., Dade City, Florida; to become a bank holding company by acquiring 100 percent of the voting shares of First National Bank of Pasco, Dade City, Florida.

C. Federal Reserve Bank of San Francisco (Kenneth R. Binning, Director, Bank Holding Company) 101 Market Street, San Francisco, California 94105-1579

1. Pierce County Bancorp, Tacoma, Washington; to become a bank holding company by acquiring 100 percent of the voting shares of Pierce Commercial Bank, Tacoma, Washington (in organization).

Board of Governors of the Federal Reserve System, March 21, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–7768 Filed 3–26–97; 8:45 am]

BILLING CODE 6210–01F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 96N–0487]

Agency Information Collection Activities; Announcement of OMB Approval

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Current Good Manufacturing Practices for Blood and Blood Components: Notification of Consignees Receiving Blood and Blood Components at Increased Risk for Transmitting HIV'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Margaret R. Wolff, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B–19, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of December 27, 1996 (61 FR 68268), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). OMB has now approved the information collection and has assigned OMB control number 0910–0336. The approval expires on February 28, 2000. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

Dated: March 19, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–7726 Filed 3–26–97; 8:45 am]

BILLING CODE 4160–01–F

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETINGS: The following advisory committee meetings are announced:

Nonprescription Drugs Advisory Committee

Date, time, and place. April 15, 1997, 8 a.m.; Holiday Inn—Gaithersburg, Goshen Room, Two Montgomery Village Ave., Gaithersburg, MD.

Type of meeting and contact person. Open committee discussion, 8 a.m. to 1:30 p.m.; open public hearing 1:30 p.m. to 2:30 p.m., unless public participation does not last that long; open committee discussion, 2:30 p.m. to 5 p.m.; closed committee deliberations, 5 p.m. to 6 p.m.; Andrea G. Neal, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Nonprescription Drugs Advisory Committee, code 12541. Please call the hotline for information concerning any possible changes.

General function of the committee. The committee reviews and evaluates available data concerning the safety and effectiveness of over-the-counter (nonprescription) human drug products for use in the treatment of a broad spectrum of human symptoms and diseases.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before April 1, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss a possible association between vaginal douching and adverse consequences. FDA is aware of a number of case-control epidemiologic studies in the literature that suggest a possible association between vaginal douching and several conditions, such as pelvic inflammatory disease, ectopic pregnancy, and cervical cancer (letter from D. Bowen, FDA, to R. W. Soller, Nonprescription Drug Manufacturers Association, LET 105, Docket No. 75N–0183, Dockets Management Branch). The committee's discussion will include issues relating to behavioral, epidemiological, and microbiological aspects of vaginal douching. Regulatory issues related to over-the-counter vaginal-douche drugs, cosmetics, and devices (douching equipment) will also be addressed.

Closed committee deliberations. The committee will review trade secret and/or confidential commercial information relevant to pending investigational new drugs applications (IND's) or new drug applications (NDA's). This portion of the meeting will be closed to permit discussion of this information. (5 U.S.C. 552b (c)(4)).

Dermatologic and Ophthalmic Drugs Advisory Committee

Date, time, and place. April 17 and 18, 1997, 8:30 a.m., Holiday Inn—Gaithersburg, Grand Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

Type of meeting and contact person. Open public hearing, April 17, 1997, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 5:30 p.m.; closed presentation of data, April 18, 1997, 8:30 a.m. to 11 a.m.; closed committee deliberations, 11 a.m. to 1 p.m.; Tracy Riley or Angie Whitacre, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Dermatologic and Ophthalmic Drugs Advisory Committee, code 12534. Please call the hotline for information concerning any possible changes.

General function of the committee. The committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of dermatologic and ophthalmic disorders.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before April 11, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the